ASBP vs ATAI

Aspire Biopharma Holdings, Inc. vs AtaiBeckley Inc. — Valuation Comparison 2026

ASBP

Biotechnology
Aspire Biopharma Holdings, Inc.
Quality
4.6
out of 10
Value Trap
22
SAFE
Price
$5.53
Last close
Models
8/13
Active
VS

ATAI

Biotechnology
AtaiBeckley Inc.
Quality
4.9
out of 10
Value Trap
Price
$4.41
Last close
Models
5/13
Active

Model-by-Model Comparison

ModelType ASBP Fair ValueASBP Upside ATAI Fair ValueATAI Upside
Bayesian DCF Intrinsic $3.92 -29.0% $1.04 -76.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.01 -95.5% $2.35 -46.8%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $7.61 +37.6% $3.99 -9.5%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ASBP vs ATAI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ASBP vs ATAI — Which Stock Is More Undervalued?

ATAI scores higher with a 4.9/10 quality rating vs ASBP's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Aspire Biopharma Holdings, Inc. (ASBP) and AtaiBeckley Inc. (ATAI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ASBP currently trades at $5.53 with a QOC of 4.6/10, while ATAI trades at $4.41 with a QOC of 4.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).